A proposed ethical framework for prescription drug benefit allocation policy

Journal of the American Pharmacists Association

Volumn 43, Issue 1, 2003, Pages 69-74

  Teagarden, J Russell ^a   Daniels, Norman ^b   Sabin, James E ^c,d  

^a Medco Health Solutions   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d HARVARD PILGRIM HEALTH CARE   (United States)

Author keywords

Benefits; Coverage; Ethics; Framework; Pharmacy; Policy

Indexed keywords

ARTICLE; ECONOMICS; ETHICS; HEALTH CARE POLICY; HEALTH INSURANCE; HUMAN; RESOURCE ALLOCATION; UNITED STATES;

HEALTH POLICY; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; RESOURCE ALLOCATION; UNITED STATES;

EID: 0037270521     PISSN: 15443191     EISSN: 15443450     Source Type: Journal    
DOI: 10.1331/10865800360467079     Document Type: Article

References (19)

1. Berndt ER. The U.S. pharmaceutical industry: why major growth in times of cost containment? Health Aff (Millwood). 2001;20(2):100-13.
2. Heffler S, Levit K, Smith S, et al. Health spending growth up in 1999: faster growth expected in the future. Health Aff (Millwood). 2001;20(2):193-203.
3. Dubois RW, Chawla AJ, Neslusan CA, et al. Explaining drug spending trends: does perception match reality? Health Aff (Millwood). 2000;19(2):231-9.
4. Burton SL, Randel L, Titlow K, Emanuel EJ. The ethics of pharmaceutical benefit management. Health Aff (Millwood). 2001;20(5):150-63.
5. Daniels N, Sabin JE. Setting Limits Fairly: Can We Learn to Share Medical Resources? New York, NY: Oxford University Press; 2002.
6. Daniels N, Sabin J. Limits to health care: fair procedures, democratic deliberation, and the legitimacy problem for insurers. Phil Pub Aff. 1997;26:303-50.
7. Daniels N. Just Health Care. New York, NY: Cambridge University Press; 1985.
8. Daniels N. Growth hormone therapy for short stature: can we support the treatment/enhancement distinction? Growth Growth Horm. 1992;8(suppl 1):46-8.
9. Sabin J, Daniels N. Determining medical necessity in mental health practice. Hastings Cent Rep. 1994;24(6):5-13.
10. Buchanan A, Brock DW, Daniels N, Wikler D. From Chance to Choice: Genetics & Justice. New York, NY: Cambridge University Press; 2000.
11. Daniels N, Sabin J. Last chance therapies and managed care. Hastings Cent Rep. 1998;28(2):27-41.
12. Daniels N. Rationing fairly: programmatic considerations. Bioethics. 1993;7:224-33.
13. Daniels N. The profit motive and the moral assessment of health care institutions. Bus Prof Ethics J. 1991;10(2):3-30.
14. Webb DJ, Muirhead GJ, Wulff M, et al. Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina. J Am Coll Cardiol. 2000;36:25-31.
15. Stewart WF, Shechter A, Lipton RB. Migraine heterogeneity: disability, pain, intensity, and attack frequency and duration. Neurology. 1994;44(suppl 4):S24-39.
16. Calabrese DC, Baldinger SL. Dose-optimization intervention yields significant drug cost savings. J Manage Care Pharm. 2002;8:146-51.
17. National Institute of Diabetes and Digestive & Kidney Diseases. Chronic Hepatitis C: Current Disease Management. Bethesda, Md: National Digestive Diseases Information Clearinghouse; 2002. NIH Publication No. 02-4230. Available at: www.niddk.nih.gov/health/digest/pubs/chrnhepc/chrnhepc.htm. Accessed September 10, 2002.
18. Prosser LA, Stinnett AA, Goldman PA, et al. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics. Ann Intern Med. 2000;132:769-79.
19. Daniels N, Sabin J. The ethics of accountability in managed care reform. Health Aff (Millwood). 1998;16(5):50-64.